logo
  

FDA Places Clinical Hold On Astellas' Phase 1/2 Trial Of AT845 In Late-Onset Pompe Disease

The U.S. Food and Drug Administration has placed a clinical hold on the FORTIS Phase 1/2 trial following the occurrence of a serious adverse event of peripheral sensory neuropathy in one of the trial participants, Astellas Pharma Inc. (ALPMY,ALPMY) said in a statement.

FORTIS is a clinical trial evaluating AT845, an investigational adeno-associated virus (AAV) gene replacement therapy in adults with Late-Onset Pompe Disease.

Pompe disease is a rare, severe, autosomal recessive metabolic disease characterized by progressive muscular degeneration.

The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects and requires additional information about the recently reported serious adverse event. To date, the serious adverse event has been classified by the site investigator as Grade 1 (mild in severity) and deemed serious due to medical significance.

Astellas noted that it is reviewing potential financial impacts of the matter for the fiscal year ending March 31, 2023.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Health insurer Humana Inc. reported Wednesday a net loss for the fourth quarter that slightly widened from last year, hurt primarily by charges associated with productivity initiatives, despite 6.6 percent revenue growth. Adjusted earnings for the quarter topped analysts' expectations, while quarterly revenues missed it by a whisker. South Plainfield, New Jersey-based Two Rivers Coffee is recalling its peanut butter single serve hot chocolate pods citing an undeclared peanut allergen, the U.S. Food Drug Administration said. The recall involves peanut butter single serve hot chocolate pods distributed as "Brooklyn Bean Peanut Butter Cup Hot Cocoa", "Pingo Peanut Butter Cookie Hot Chocolate" and ... Shares of Novartis AG were losing around 2 percent in the early morning trading in Switzerland after the drug major reported Wednesday sharply lower profit in its fourth quarter with weak sales as well as the absence of prior year's hefty Roche income. Adjusted earnings, however, topped market estimates, while top line missed their view. Further, the company announced higher dividend...
Follow RTT